Carmela Caputo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carmela Caputo has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Warrick J. Inder
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
6 shared publications Yi Yuen Wang
Department of Neurosurgery, St Vincent's Private Hospital, Melbourne, VIC, Australia
4 shared publicationsDavid Prior
Department of Cardiology, St. Vincent's Hospital Melbourne and The University of Melbourne, Victoria, Australia
2 shared publicationsPeter McNeill
Department of Neurosurgery, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
2 shared publications- Tom Sutherland
Medical Imaging Department, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
2 shared publications Abhishek Easwaran
Department of Biostatistics, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
1 shared publication
Latest Publications
- Open Access
- 3 September 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (10)
Papillary craniopharyngioma following an initial diagnosis of Rathke cleft cyst: a case report and narrative review
A 59-year-old man presented with a giant suprasellar cystic lesion causing obstructive hydrocephalus. Radiological and intraoperative findings suggested a cystic craniopharyngioma (CP); however, histopathology was interpreted as most consistent with a Rathke cleft cyst (RCC). Six years later, surveillance imaging demonstrated recurrence as a new mixed solid-cystic suprasellar mass with infundibular thickening. Histopathology showed papillary architecture with diffuse BRAF V600E immunopositivity, confirming papillary craniopharyngioma (PCP). The original specimen was subsequently re-examined, finding positivity for BRAF V600E staining and microscopic features supporting the diagnosis of PCP rather than RCC. We conducted a narrative review of published cases describing diagnostic overlap between RCC and CP. Several reports describe lesions with mixed histological features and cases initially labeled as RCC that were later reclassified as CP following additional sampling or modern molecular testing. Notably, nearly all such cases involved PCP rather than adamantinomatous CP. These observations suggest that some lesions initially diagnosed as RCC may represent under-recognized PCP, although a biological relationship between the 2 entities cannot be excluded. This case underscores the importance of integrating radiological, operative, and pathological findings when evaluating suprasellar cysts, additionally, the value of pathological reassessment—particularly BRAF V600E testing—when a presumed RCC demonstrates atypical features or interval progression.
- 3 September 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (10)
Open AccessPapillary craniopharyngioma following an initial diagnosis of Rathke cleft cyst: a case report and narrative review
A 59-year-old man presented with a giant suprasellar cystic lesion causing obstructive hydrocephalus. Radiological and intraoperative findings suggested a cystic craniopharyngioma (CP); however, histopathology was interpreted as most consistent with a Rathke cleft cyst (RCC). Six years later, surveillance imaging demonstrated recurrence as a new mixed solid-cystic suprasellar mass with infundibular thickening. Histopathology showed papillary architecture with diffuse BRAF V600E immunopositivity, confirming papillary craniopharyngioma (PCP). The original specimen was subsequently re-examined, finding positivity for BRAF V600E staining and microscopic features supporting the diagnosis of PCP rather than RCC. We conducted a narrative review of published cases describing diagnostic overlap between RCC and CP. Several reports describe lesions with mixed histological features and cases initially labeled as RCC that were later reclassified as CP following additional sampling or modern molecular testing. Notably, nearly all such cases involved PCP rather than adamantinomatous CP. These observations suggest that some lesions initially diagnosed as RCC may represent under-recognized PCP, although a biological relationship between the 2 entities cannot be excluded. This case underscores the importance of integrating radiological, operative, and pathological findings when evaluating suprasellar cysts, additionally, the value of pathological reassessment—particularly BRAF V600E testing—when a presumed RCC demonstrates atypical features or interval progression.
- Open Access
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5)
Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency
This report describes a 53-year-old female individual with known arginine vasopressin deficiency (AVP-D) due to a recurrent Rathke cleft cyst (RCC), with asymptomatic severe hyponatremia (sodium 121 mEq/L [SI: 121 mmol/L]; reference range 135-145 mEq/L [SI: 135-145 mmol/L]) in the setting of several months of tirzepatide use for weight loss. On review of the literature this is the third case of severe hyponatremia (sodium ≤125 mEq/L [SI: ≤125 mmol/L]) reported with the use of tirzepatide and first case in someone with AVP-D. Although hyponatremia associated with tirzepatide is rare, it poses a significant risk for individuals with AVP-D, who are already predisposed to hyponatremia. Clinicians should remain vigilant regarding this potential complication, provide education on desmopressin escape strategies, and carefully consider reductions in desmopressin dosing when co-administering with tirzepatide.
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5)
Open AccessTirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency
This report describes a 53-year-old female individual with known arginine vasopressin deficiency (AVP-D) due to a recurrent Rathke cleft cyst (RCC), with asymptomatic severe hyponatremia (sodium 121 mEq/L [SI: 121 mmol/L]; reference range 135-145 mEq/L [SI: 135-145 mmol/L]) in the setting of several months of tirzepatide use for weight loss. On review of the literature this is the third case of severe hyponatremia (sodium ≤125 mEq/L [SI: ≤125 mmol/L]) reported with the use of tirzepatide and first case in someone with AVP-D. Although hyponatremia associated with tirzepatide is rare, it poses a significant risk for individuals with AVP-D, who are already predisposed to hyponatremia. Clinicians should remain vigilant regarding this potential complication, provide education on desmopressin escape strategies, and carefully consider reductions in desmopressin dosing when co-administering with tirzepatide.
- Open Access
- 8 January 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (2)
Medication-Induced Severe Hyponatremia After Elective Surgery in a Patient With Known Arginine Vasopressin Deficiency
Arginine vasopressin deficiency (AVP-D) is a rare disorder associated with a considerable risk of dysnatremia. This case involves a 59-year-old woman with idiopathic AVP-D and secondary hypocortisolemia, who developed severe hyponatremia after elective knee replacement. Postoperative pain management included nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. On day 4 of her admission, serum sodium concentration was 128 mEq/L (SI: 128 mmol/L) (reference range, 135-145 mEq/L [SI: 135-145 mmol/L]), but this was not reviewed. Feeling unwell that evening, she self-administered 200 mcg desmopressin; the next morning her sodium was 119 mEq/L (SI: 119 mmol/L); despite withholding all regular desmopressin doses for that day and the commencement of the expectant polyuria, hours later her sodium fell to 113 mEq/L (SI: 113 mmol/L). Emergency treatment involved fluid restriction and hypertonic saline, raising the sodium to 120 mEq/L (SI: 120 mmol/L) in 6 hours. Desmopressin 100 mcg was then restarted to clamp rapid overcorrection. Over 30 hours, sodium normalized with further desmopressin given as polyuria recurred: no neurological issues arose. Literature review found 14 cases of NSAIDs and opioids causing acute and severe hyponatremia in those taking desmopressin, highlighting the importance for clinicians and patients to be aware of these medication interactions.
- 8 January 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (2)
Open AccessMedication-Induced Severe Hyponatremia After Elective Surgery in a Patient With Known Arginine Vasopressin Deficiency
Arginine vasopressin deficiency (AVP-D) is a rare disorder associated with a considerable risk of dysnatremia. This case involves a 59-year-old woman with idiopathic AVP-D and secondary hypocortisolemia, who developed severe hyponatremia after elective knee replacement. Postoperative pain management included nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. On day 4 of her admission, serum sodium concentration was 128 mEq/L (SI: 128 mmol/L) (reference range, 135-145 mEq/L [SI: 135-145 mmol/L]), but this was not reviewed. Feeling unwell that evening, she self-administered 200 mcg desmopressin; the next morning her sodium was 119 mEq/L (SI: 119 mmol/L); despite withholding all regular desmopressin doses for that day and the commencement of the expectant polyuria, hours later her sodium fell to 113 mEq/L (SI: 113 mmol/L). Emergency treatment involved fluid restriction and hypertonic saline, raising the sodium to 120 mEq/L (SI: 120 mmol/L) in 6 hours. Desmopressin 100 mcg was then restarted to clamp rapid overcorrection. Over 30 hours, sodium normalized with further desmopressin given as polyuria recurred: no neurological issues arose. Literature review found 14 cases of NSAIDs and opioids causing acute and severe hyponatremia in those taking desmopressin, highlighting the importance for clinicians and patients to be aware of these medication interactions.
- Open Access
- 17 March 2021
- Published by Wiley in Clinical Endocrinology
- Vol. 95 (1) , 125-133
Reducing adverse events associated with the glucagon stimulation test for the assessment of growth hormone deficiency in adults with a high prevalence of pituitary hormone deficiencies
Design: A retrospective review of the adverse events (AEs) in 78 patients during the glucagon stimulation test (GST) for the assessment of growth hormone deficiency (GHD) before and after protocol amendments which aimed to reduce AEs in a group of patients with a high prevalence of pituitary hormone deficiencies.Patients: Based on our observations of frequent AEs during the standard GST protocol in an initial 25 patients (cohort 1), a modified protocol was introduced to include the routine administration of 20 mg of hydrocortisone pre‐GST in a subsequent 53 patients (cohort 2). Post hoc analysis of the effect of glucocorticoid dosing pre‐GST on AEs was examined in those receiving n = 19) vs ≥20 mg hydrocortisone (group B, n = 59).Measurements: AEs including hypotension, hypoglycaemia and nausea/vomiting.Results: Of the 78 patients undergoing the GST, 79% had ≥2 hormone deficiencies. Rates of AEs were 41% vs 30% for hypotension, 60% vs 28% for hypoglycaemia (p < .05) and 20% vs 13% for nausea/vomiting in cohort 1 compared with cohort 2, respectively. Post hoc analysis revealed lower rates of AEs in those receiving ≥20 mg hydrocortisone (group B) compared to those receiving p < .001) and hypotension (50% vs 27%, p = .05). Similar numbers of patients in group A and group B met criteria for GHD.Conclusions: In patients with a high prevalence of pituitary deficiencies, a modified GST protocol of additional stress dose glucocorticoid attenuated the frequency of AEs without appearing to compromise the performance of the GST.
- 17 March 2021
- Published by Wiley in Clinical Endocrinology
- Vol. 95 (1) , 125-133
Open AccessReducing adverse events associated with the glucagon stimulation test for the assessment of growth hormone deficiency in adults with a high prevalence of pituitary hormone deficiencies
Design: A retrospective review of the adverse events (AEs) in 78 patients during the glucagon stimulation test (GST) for the assessment of growth hormone deficiency (GHD) before and after protocol amendments which aimed to reduce AEs in a group of patients with a high prevalence of pituitary hormone deficiencies.Patients: Based on our observations of frequent AEs during the standard GST protocol in an initial 25 patients (cohort 1), a modified protocol was introduced to include the routine administration of 20 mg of hydrocortisone pre‐GST in a subsequent 53 patients (cohort 2). Post hoc analysis of the effect of glucocorticoid dosing pre‐GST on AEs was examined in those receiving n = 19) vs ≥20 mg hydrocortisone (group B, n = 59).Measurements: AEs including hypotension, hypoglycaemia and nausea/vomiting.Results: Of the 78 patients undergoing the GST, 79% had ≥2 hormone deficiencies. Rates of AEs were 41% vs 30% for hypotension, 60% vs 28% for hypoglycaemia (p < .05) and 20% vs 13% for nausea/vomiting in cohort 1 compared with cohort 2, respectively. Post hoc analysis revealed lower rates of AEs in those receiving ≥20 mg hydrocortisone (group B) compared to those receiving p < .001) and hypotension (50% vs 27%, p = .05). Similar numbers of patients in group A and group B met criteria for GHD.Conclusions: In patients with a high prevalence of pituitary deficiencies, a modified GST protocol of additional stress dose glucocorticoid attenuated the frequency of AEs without appearing to compromise the performance of the GST.
- 1 April 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (10) , 4319-4320
Letter to the Editor: “A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline”
Carmela Caputo, Warrick J Inder; Letter to the Editor: [A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients with Hyperprolactinemia Treated w
- 1 April 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (10) , 4319-4320
Letter to the Editor: “A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline”
Carmela Caputo, Warrick J Inder; Letter to the Editor: [A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients with Hyperprolactinemia Treated w
- Open Access
- 11 July 2018
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 2 (8) , 965-969
The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening
A decade on from the alarming association of cabergoline associated valvulopathy (CAV) in Parkinson’s disease, only 2 confirmed cases have occurred in prolactinoma patients. Routine screening for CAV by echocardiogram has not proven to be of diagnostic utility, has several limitations and is not widely practised. We have previously highlighted the value of annual cardiovascular examination as screening tool for CAV in prolactinoma patients. We present a case to highlight the value of the cardiovascular examination, which is now the third confirmed case of CAV. A 52 year old female with a 25 year history of macroprolactinoma had received multimodal treatment including surgery, radiosurgery and medical therapy. Her medical therapy initially consisted of bromocriptine followed by cabergoline. The cabergoline dose was 6mg weekly, and in 2009 the cumulative dose of 3272mg when an echocardiogram showed no evidence of valvular disease. A routine cardiovascular examination in clinic detected a new murmur in 2016. Echocardiogram demonstrated new onset mild- moderate aortic regurgitation, with a thickened and restricted valve consistent with CAV. Cumulative dose of cabergoline at this time was 4192mg. Follow up echocardiogram at six monthly intervals showed progression to moderate-severe aortic regurgitation, which has now stabilized. Cabergoline therapy was weaned and stopped completely in April 2017. Annual cardiovascular examination is the best screening test for CAV and can change the course of patient management. Echocardiograms should be reserved for patients with a new onset cardiac murmur or a high cumulative dose of cabergoline.
- 11 July 2018
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 2 (8) , 965-969
Open AccessThe Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening
A decade on from the alarming association of cabergoline associated valvulopathy (CAV) in Parkinson’s disease, only 2 confirmed cases have occurred in prolactinoma patients. Routine screening for CAV by echocardiogram has not proven to be of diagnostic utility, has several limitations and is not widely practised. We have previously highlighted the value of annual cardiovascular examination as screening tool for CAV in prolactinoma patients. We present a case to highlight the value of the cardiovascular examination, which is now the third confirmed case of CAV. A 52 year old female with a 25 year history of macroprolactinoma had received multimodal treatment including surgery, radiosurgery and medical therapy. Her medical therapy initially consisted of bromocriptine followed by cabergoline. The cabergoline dose was 6mg weekly, and in 2009 the cumulative dose of 3272mg when an echocardiogram showed no evidence of valvular disease. A routine cardiovascular examination in clinic detected a new murmur in 2016. Echocardiogram demonstrated new onset mild- moderate aortic regurgitation, with a thickened and restricted valve consistent with CAV. Cumulative dose of cabergoline at this time was 4192mg. Follow up echocardiogram at six monthly intervals showed progression to moderate-severe aortic regurgitation, which has now stabilized. Cabergoline therapy was weaned and stopped completely in April 2017. Annual cardiovascular examination is the best screening test for CAV and can change the course of patient management. Echocardiograms should be reserved for patients with a new onset cardiac murmur or a high cumulative dose of cabergoline.
- Open Access
- 1 January 2018
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 9 (1) , 15
Suprasellar keratinous cyst: A case report and review on its radiological features and treatment outcome
Chronic endocrine disturbances can be the presenting complaints of a suprasellar EC, whose T1-weighted MRI appearance can be non-specific, mimicking other differential diagnoses, such as a Rathke's cleft cyst. However, the T2-weighted MRI appearances of ECs are generally hyper-intense and lesions show diffusion restriction. Treatment is surgical and yields good outcomes in most cases reported.
- 1 January 2018
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 9 (1) , 15
Open AccessSuprasellar keratinous cyst: A case report and review on its radiological features and treatment outcome
Chronic endocrine disturbances can be the presenting complaints of a suprasellar EC, whose T1-weighted MRI appearance can be non-specific, mimicking other differential diagnoses, such as a Rathke's cleft cyst. However, the T2-weighted MRI appearances of ECs are generally hyper-intense and lesions show diffusion restriction. Treatment is surgical and yields good outcomes in most cases reported.
- 31 May 2017
- Published by Wiley in Clinical Endocrinology
- Vol. 87 (3) , 264-271
Younger age is a risk factor for regrowth and recurrence of nonfunctioning pituitary macroadenomas: Results from a single Australian centre
Summary: Objective: The natural history of nonfunctioning pituitary macroadenomas (NFPMA) after surgical resection is variable, with guidelines unable to define the duration of radiological follow‐up. In this first Australian series, we identify risk factors for regrowth/recurrence of NFPMA to assist with guiding recommendations for long‐term follow‐up.Design: Retrospective analysis of all radiotherapy‐naïve cases with NFPMA resected between 1995 and 2013.Patients: One hundred and twenty‐three cases had both ≥2 postoperative scans and ≥12‐month follow‐up.Measurements: Regrowth was defined as any sustained increase in diameter of residual adenoma or recurrence as any new adenoma occurring post complete resection on serial pituitary MRI.Results: Median follow‐up time was 48 months (interquartile range [IQR]: 31‐86). Overall regrowth/recurrence occurred in 29% (36/123). Regrowth occurred in 40% (30/76) at a median time of 44.5 months (IQR 22‐80) compared to recurrence of 12.5% (6/48; P=.003), occurring at a median time of 48 months (IQR 12‐96; P=.7). Further treatment was required in 66.7% and 56.7%, respectively (=1.0). Risk factors for regrowth/recurrence by multivariate analysis were presence of residual disease and younger age at presentation. The longest time for regrowth was 168 months (14 years) and recurrence 156 months (13 years).Conclusions: Presence of postoperative residual adenoma and younger age at presentation are the main predictors of regrowth/recurrence in NFPMA. Long‐term serial imaging is required to detect regrowth and recurrence in younger patients and those with residual disease. Most regrowth/recurrences will occur within 10 years of follow‐up.
- 31 May 2017
- Published by Wiley in Clinical Endocrinology
- Vol. 87 (3) , 264-271
Younger age is a risk factor for regrowth and recurrence of nonfunctioning pituitary macroadenomas: Results from a single Australian centre
Summary: Objective: The natural history of nonfunctioning pituitary macroadenomas (NFPMA) after surgical resection is variable, with guidelines unable to define the duration of radiological follow‐up. In this first Australian series, we identify risk factors for regrowth/recurrence of NFPMA to assist with guiding recommendations for long‐term follow‐up.Design: Retrospective analysis of all radiotherapy‐naïve cases with NFPMA resected between 1995 and 2013.Patients: One hundred and twenty‐three cases had both ≥2 postoperative scans and ≥12‐month follow‐up.Measurements: Regrowth was defined as any sustained increase in diameter of residual adenoma or recurrence as any new adenoma occurring post complete resection on serial pituitary MRI.Results: Median follow‐up time was 48 months (interquartile range [IQR]: 31‐86). Overall regrowth/recurrence occurred in 29% (36/123). Regrowth occurred in 40% (30/76) at a median time of 44.5 months (IQR 22‐80) compared to recurrence of 12.5% (6/48; P=.003), occurring at a median time of 48 months (IQR 12‐96; P=.7). Further treatment was required in 66.7% and 56.7%, respectively (=1.0). Risk factors for regrowth/recurrence by multivariate analysis were presence of residual disease and younger age at presentation. The longest time for regrowth was 168 months (14 years) and recurrence 156 months (13 years).Conclusions: Presence of postoperative residual adenoma and younger age at presentation are the main predictors of regrowth/recurrence in NFPMA. Long‐term serial imaging is required to detect regrowth and recurrence in younger patients and those with residual disease. Most regrowth/recurrences will occur within 10 years of follow‐up.
- Open Access
- 27 April 2017
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2017
An intrasellar pituitary adenoma–gangliocytoma presenting as acromegaly
Summary: Most cases of acromegaly are due to growth hormone (GH)-secreting pituitary adenomas arising from somatotroph cells. Mixed pituitary adenoma and gangliocytoma tumours are rare and typically associated with hormonal hypersecretion, most commonly GH excess. Differentiating these mixed tumours from conventional pituitary adenomas can be difficult pre-operatively, and careful histological analysis after surgical resection is key to differentiating the two entities. There is little literature addressing the possible mechanisms for the development of mixed pituitary adenoma–gangliocytomas; however, several hypotheses have been proposed. It still remains unclear if these mixed tumours differ from a clinical perspective to pituitary adenomas; however, the additional neural component of the gangliocytoma does not appear to modify the aggressiveness or risk of recurrence after surgical resection. We report a unique case of acromegaly secondary to a mixed GH-secreting pituitary adenoma, co-existing with an intrasellar gangliocytoma. Learning points: Acromegaly due to a mixed GH-secreting pituitary adenoma and intrasellar gangliocytoma is rare. These mixed tumours cannot be distinguished easily from ordinary pituitary adenomas on the basis of clinical, endocrine or neuroradiologic findings, and histological analysis is required for a definitive diagnosis. Surgical resection is usually sufficient to provide cure, without the need for adjuvant therapy. These mixed tumours appear to have a good prognosis although the natural history is not well defined. The pathogenesis of these mixed tumours remains debatable, and ongoing research is required.
- 27 April 2017
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2017
Open AccessAn intrasellar pituitary adenoma–gangliocytoma presenting as acromegaly
Summary: Most cases of acromegaly are due to growth hormone (GH)-secreting pituitary adenomas arising from somatotroph cells. Mixed pituitary adenoma and gangliocytoma tumours are rare and typically associated with hormonal hypersecretion, most commonly GH excess. Differentiating these mixed tumours from conventional pituitary adenomas can be difficult pre-operatively, and careful histological analysis after surgical resection is key to differentiating the two entities. There is little literature addressing the possible mechanisms for the development of mixed pituitary adenoma–gangliocytomas; however, several hypotheses have been proposed. It still remains unclear if these mixed tumours differ from a clinical perspective to pituitary adenomas; however, the additional neural component of the gangliocytoma does not appear to modify the aggressiveness or risk of recurrence after surgical resection. We report a unique case of acromegaly secondary to a mixed GH-secreting pituitary adenoma, co-existing with an intrasellar gangliocytoma. Learning points: Acromegaly due to a mixed GH-secreting pituitary adenoma and intrasellar gangliocytoma is rare. These mixed tumours cannot be distinguished easily from ordinary pituitary adenomas on the basis of clinical, endocrine or neuroradiologic findings, and histological analysis is required for a definitive diagnosis. Surgical resection is usually sufficient to provide cure, without the need for adjuvant therapy. These mixed tumours appear to have a good prognosis although the natural history is not well defined. The pathogenesis of these mixed tumours remains debatable, and ongoing research is required.